Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 324

Similar articles for PubMed (Select 20236548)

1.

Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons.

Jackson LA, Gaglani MJ, Keyserling HL, Balser J, Bouveret N, Fries L, Treanor JJ.

BMC Infect Dis. 2010 Mar 17;10:71. doi: 10.1186/1471-2334-10-71.

2.

Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years.

Kieninger D, Sheldon E, Lin WY, Yu CJ, Bayas JM, Gabor JJ, Esen M, Fernandez Roure JL, Narejos Perez S, Alvarez Sanchez C, Feng Y, Claeys C, Peeters M, Innis BL, Jain V.

BMC Infect Dis. 2013 Jul 24;13:343. doi: 10.1186/1471-2334-13-343.

3.

Safety and immunogenicity of trivalent inactivated influenza vaccine in infants: a randomized double-blind placebo-controlled study.

Englund JA, Walter E, Black S, Blatter M, Nyberg J, Ruben FL, Decker MD; GRC28 Study Team.

Pediatr Infect Dis J. 2010 Feb;29(2):105-10. doi: 10.1097/INF.0b013e3181b84c34.

PMID:
19934787
4.

Efficacy of inactivated split-virus influenza vaccine against culture-confirmed influenza in healthy adults: a prospective, randomized, placebo-controlled trial.

Beran J, Vesikari T, Wertzova V, Karvonen A, Honegr K, Lindblad N, Van Belle P, Peeters M, Innis BL, Devaster JM.

J Infect Dis. 2009 Dec 15;200(12):1861-9. doi: 10.1086/648406.

5.

Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults.

Greenberg DP, Robertson CA, Noss MJ, Blatter MM, Biedenbender R, Decker MD.

Vaccine. 2013 Jan 21;31(5):770-6. doi: 10.1016/j.vaccine.2012.11.074. Epub 2012 Dec 8.

PMID:
23228813
6.

Challenge of conducting a placebo-controlled randomized efficacy study for influenza vaccine in a season with low attack rate and a mismatched vaccine B strain: a concrete example.

Beran J, Wertzova V, Honegr K, Kaliskova E, Havlickova M, Havlik J, Jirincova H, Van Belle P, Jain V, Innis B, Devaster JM.

BMC Infect Dis. 2009 Jan 17;9:2. doi: 10.1186/1471-2334-9-2.

7.

A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness.

Langley JM, Aoki F, Ward BJ, McGeer A, Angel JB, Stiver G, Gorfinkel I, Shu D, White L, Lasko B, Dzongowski P, Papp K, Alexander M, Boivin G, Fries L.

Vaccine. 2011 Feb 24;29(10):1921-8. doi: 10.1016/j.vaccine.2010.12.100. Epub 2011 Jan 8.

PMID:
21219987
8.

Immunogenicity, safety and reactogenicity of a mammalian cell-culture-derived influenza vaccine in healthy children and adolescents three to seventeen years of age.

Vesikari T, Block SL, Guerra F, Lattanzi M, Holmes S, Izu A, Gaitatzis N, Hilbert AK, Groth N.

Pediatr Infect Dis J. 2012 May;31(5):494-500. doi: 10.1097/INF.0b013e31824bb179.

PMID:
22301476
9.

Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years: a phase III, randomized trial.

Tinoco JC, Pavia-Ruz N, Cruz-Valdez A, Aranza Doniz C, Chandrasekaran V, Dewé W, Liu A, Innis BL, Jain VK.

Vaccine. 2014 Mar 14;32(13):1480-7. doi: 10.1016/j.vaccine.2014.01.022. Epub 2014 Jan 28.

10.

Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults.

Pépin S, Donazzolo Y, Jambrecina A, Salamand C, Saville M.

Vaccine. 2013 Nov 12;31(47):5572-8. doi: 10.1016/j.vaccine.2013.08.069. Epub 2013 Sep 7.

PMID:
24016810
11.
12.

Clinical efficacy of cell culture–derived and egg‐derived inactivated subunit influenza vaccines in healthy adults.

Frey S, Vesikari T, Szymczakiewicz-Multanowska A, Lattanzi M, Izu A, Groth N, Holmes S.

Clin Infect Dis. 2010 Nov 1;51(9):997-1004. doi: 10.1086/656578.

13.

Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults.

Beran J, Peeters M, Dewé W, Raupachová J, Hobzová L, Devaster JM.

BMC Infect Dis. 2013 May 20;13:224. doi: 10.1186/1471-2334-13-224.

14.

Inactivated split-virion seasonal influenza vaccine (Fluarix): a review of its use in the prevention of seasonal influenza in adults and the elderly.

Curran MP, Leroux-Roels I.

Drugs. 2010 Aug 20;70(12):1519-43. doi: 10.2165/11205020-000000000-00000. Review.

PMID:
20687619
15.

A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years.

Domachowske JB, Pankow-Culot H, Bautista M, Feng Y, Claeys C, Peeters M, Innis BL, Jain V.

J Infect Dis. 2013 Jun 15;207(12):1878-87. doi: 10.1093/infdis/jit091. Epub 2013 Mar 7.

16.

Live attenuated influenza vaccine (FluMist®; Fluenz™): a review of its use in the prevention of seasonal influenza in children and adults.

Carter NJ, Curran MP.

Drugs. 2011 Aug 20;71(12):1591-622. doi: 10.2165/11206860-000000000-00000. Review.

PMID:
21861544
17.

Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: a randomized, placebo-controlled trial.

Treanor JJ, El Sahly H, King J, Graham I, Izikson R, Kohberger R, Patriarca P, Cox M.

Vaccine. 2011 Oct 13;29(44):7733-9. doi: 10.1016/j.vaccine.2011.07.128. Epub 2011 Aug 9.

PMID:
21835220
18.

Immunogenicity and safety of inactivated quadrivalent and trivalent influenza vaccines in children 18-47 months of age.

Rodriguez Weber MA, Claeys C, Aranza Doniz C, Feng Y, Innis BL, Jain VK, Peeters M.

Pediatr Infect Dis J. 2014 Dec;33(12):1262-9. doi: 10.1097/INF.0000000000000463.

PMID:
25386965
19.

Efficacy and immunogenicity of influenza vaccine in HIV-infected children: a randomized, double-blind, placebo controlled trial.

Madhi SA, Dittmer S, Kuwanda L, Venter M, Cassim H, Lazarus E, Thomas T, Liberty A, Treurnich F, Cutland CL, Weinberg A, Violari A.

AIDS. 2013 Jan 28;27(3):369-79. doi: 10.1097/QAD.0b013e32835ab5b2.

PMID:
23032417
20.

AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial.

McElhaney JE, Beran J, Devaster JM, Esen M, Launay O, Leroux-Roels G, Ruiz-Palacios GM, van Essen GA, Caplanusi A, Claeys C, Durand C, Duval X, El Idrissi M, Falsey AR, Feldman G, Frey SE, Galtier F, Hwang SJ, Innis BL, Kovac M, Kremsner P, McNeil S, Nowakowski A, Richardus JH, Trofa A, Oostvogels L; Influence65 study group.

Lancet Infect Dis. 2013 Jun;13(6):485-96. doi: 10.1016/S1473-3099(13)70046-X. Epub 2013 Mar 19.

PMID:
23518156
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk